Administration of the licensed MF59-containing vaccines, e.g. Fluad™ or Addigrip™ or virosome-based influenza vaccines such as Inflexal V™, InfectoVac Flu™ or Invivac™ during the 2006-2007 influenza season. 
Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. 
Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination with H5N1 vaccine. 
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first administration of the study vaccine. 
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). 
History of chronic alcohol consumption and/or drug abuse. 
History of hypersensitivity to vaccines. 
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (including egg and thiomersal allergy). 
Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. 
Acute disease at the time of enrolment. 
Serious chronic disease including any medically significant chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder, as determined by medical history and physical examination. 
Administration of immunoglobulins and/or any blood products within the three months preceding the first vaccination or during the study. 
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to the first vaccination, or planned use during the study period. 
Any condition which, in the opinion of the investigator, prevents the subject from participation in the study.       
    

NCT00397215_exc_T1
Drug
MF59-containing vaccines
NCT00397215_exc_T2
Drug
Fluad
NCT00397215_exc_T3
Drug
Addigrip
NCT00397215_exc_T4
Drug
virosome-based influenza vaccines
NCT00397215_exc_T5
Drug
Inflexal V
NCT00397215_exc_T6
Drug
InfectoVac Flu
NCT00397215_exc_T7
Drug
Invivac
NCT00397215_exc_T8
Temporal
during the 2006-2007 influenza season
NCT00397215_exc_T9
Scope
Inflexal V™, InfectoVac Flu™ or Invivac™
NCT00397215_exc_T10
Scope
Fluad™ or Addigrip™
NCT00397215_exc_T11
Scope
MF59-containing vaccines, e.g. Fluad™ or Addigrip™ or virosome-based influenza vaccines such as Inflexal V™, InfectoVac Flu™ or Invivac™
NCT00397215_exc_T12
Temporal
within 2 weeks prior to enrolment in this study
NCT00397215_exc_T13
Temporal
within 4 weeks prior to enrolment in this study
NCT00397215_exc_T14
Drug
inactivated vaccines
NCT00397215_exc_T15
Drug
live vaccines
NCT00397215_exc_T16
Drug
licensed vaccines
NCT00397215_exc_T17
Scope
within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study
NCT00397215_exc_T18
Drug
vaccine
NCT00397215_exc_T19
Qualifier
foreseen by the study protocol
NCT00397215_exc_T20
Negation
not
NCT00397215_exc_T21
Temporal
up to 30 days
NCT00397215_exc_T22
Drug
vaccination
NCT00397215_exc_T23
Value
second
NCT00397215_exc_T24
Drug
H5N1 vaccine
NCT00397215_exc_T25
Temporal
more than 14 days
NCT00397215_exc_T26
Qualifier
Chronic
NCT00397215_exc_T27
Drug
immunosuppressants
NCT00397215_exc_T28
Drug
other immune-modifying drugs
NCT00397215_exc_T29
Temporal
within six months prior
NCT00397215_exc_T30
Scope
immunosuppressants or other immune-modifying drugs
NCT00397215_exc_T31
Condition
immunosuppressive condition
NCT00397215_exc_T32
Condition
immunodeficient condition
NCT00397215_exc_T33
Qualifier
confirmed
NCT00397215_exc_T34
Qualifier
suspected
NCT00397215_exc_T35
Scope
confirmed or suspected
NCT00397215_exc_T36
Scope
immunosuppressive or immunodeficient condition
NCT00397215_exc_T37
Condition
chronic alcohol consumption
NCT00397215_exc_T38
Condition
drug abuse
NCT00397215_exc_T39
Observation
History
NCT00397215_exc_T40
Scope
chronic alcohol consumption and/or drug abuse
NCT00397215_exc_T41
Condition
hypersensitivity to vaccines
NCT00397215_exc_T42
Observation
History
NCT00397215_exc_T43
Condition
allergic disease
NCT00397215_exc_T44
Condition
allergic reactions
NCT00397215_exc_T45
Observation
History
NCT00397215_exc_T46
Scope
egg and thiomersal allergy
NCT00397215_exc_T47
Condition
egg allergy
NCT00397215_exc_T48
Condition
thiomersal allergy
NCT00397215_exc_T49
Scope
allergic disease or reactions
NCT00397215_exc_T51
Condition
cardiovascular functional abnormality
NCT00397215_exc_T52
Condition
hepatic functional abnormality
NCT00397215_exc_T53
Condition
renal functional abnormality
NCT00397215_exc_T50
Condition
pulmonary functional abnormality
NCT00397215_exc_T54
Condition
Acute disease
NCT00397215_exc_T55
Temporal
at the time of enrolment
NCT00397215_exc_T56
Condition
chronic pulmonary disorder
NCT00397215_exc_T57
Condition
chronic cardiovascular disorder
NCT00397215_exc_T58
Condition
chronic renal disorder
NCT00397215_exc_T59
Condition
chronic neurological disorder
NCT00397215_exc_T60
Condition
chronic psychiatric disorder
NCT00397215_exc_T61
Condition
chronic metabolic disorder
NCT00397215_exc_T62
Drug
immunoglobulins
NCT00397215_exc_T63
Drug
any blood products
NCT00397215_exc_T64
Temporal
within the three months preceding the first vaccination
NCT00397215_exc_T65
Scope
immunoglobulins and/or any blood products
NCT00397215_exc_T66
Condition
condition
NCT00397215_exc_T67
Qualifier
which prevents the subject from participation in the study
NCT00397215_exc_T70
Qualifier
investigational
NCT00397215_exc_T71
Qualifier
non-registered
NCT00397215_exc_T72
Drug
product
NCT00397215_exc_T73
Scope
investigational or non-registered
NCT00397215_exc_T74
Drug
drug
NCT00397215_exc_T75
Drug
vaccine
NCT00397215_exc_T76
Scope
drug or vaccine
NCT00397215_exc_T77
Negation
other than
NCT00397215_exc_T78
Drug
study vaccine(s)
NCT00397215_exc_T79
Qualifier
other than the study vaccine(s)
NCT00397215_exc_T80
Temporal
within 30 days prior to the first vaccination
NCT00397215_exc_T81
Reference_point
the first vaccination
NCT00397215_exc_T82
Procedure
vaccination
NCT00397215_exc_T83
Temporal
first
NCT00397215_exc_T84
Mood
planned
NCT00397215_exc_T85
Temporal
during the study period
NCT00397215_exc_T86
Procedure
use
NCT00397215_exc_T87
Qualifier
Serious
NCT00397215_exc_T88
Condition
chronic disease
NCT00397215_exc_T89
Scope
chronic pulmonary, cardiovascular, renal, neurological, psychiatric or metabolic disorder
NCT00397215_exc_T90
Temporal
during the study
NCT00397215_exc_T91
Reference_point
the first vaccination
NCT00397215_exc_T92
Procedure
vaccination
NCT00397215_exc_T93
Temporal
first
NCT00397215_exc_T94
Scope
within the three months preceding the first vaccination or during the study
NCT00397215_exc_T95
Reference_point
the study